| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
The administration of Lycorine hydrochloride (0-25 μM; 48 h; C8161 cells) resulted in a dose-dependent considerable inhibition of VE-cadherin expression and a minor reduction of Sema4D expression in C8161 cells. The other six genes' expression is unaffected, albeit [1]. In C8161 cells, treatment with lycorine hydrochloride (0-25 μM) for 48 hours dramatically (dose-dependently) decreased the levels of VE-cadherin [1].
|
|---|---|
| ln Vivo |
Treatment with lycorine hydrochloride (0–15 μg; subcutaneous injection; duration: 14 days; BALB/C nude mice) inhibits the mimicking of tumor angiogenesis caused by melanoma cells [1].
|
| Cell Assay |
RT-PCR[1]
Cell Types: C8161 Cell Tested Concentrations: 0 μM, 1.56 μM, 3.13 μM, 6.25 μM, 12.5 μM, 25 μM Incubation Duration: 48 hrs (hours) Experimental Results: Dramatically inhibited the expression of VE-cadherin in a dose-dependent manner manner, and also slightly diminished the expression of Sema4D in C8161 cells. Western Blot Analysis[1] Cell Types: C8161 Cell Tested Concentrations: 0 μM, 1.56 μM, 3.13 μM, 6.25 μM, 12.5 μM, 25 μM Incubation Duration: 48 hrs (hours) Experimental Results: The level of VE-cadherin protein in C8161 cells at a certain dose was significant Reduce reliance on fashion. |
| Animal Protocol |
Animal/Disease Models: 6 to 8 weeks old BALB/C nude mice [1]
Doses: 0μg, 7.5μg, 15μg Route of Administration: subcutaneous injection; continued for 14 days Experimental Results: Inhibition of tumor angiogenesis mimicry mediated by melanoma cells effect. |
| References |
|
| Molecular Formula |
C16H17NO4
|
|---|---|
| Molecular Weight |
287.3105
|
| Exact Mass |
323.092
|
| CAS # |
2188-68-3
|
| Related CAS # |
Lycorine;476-28-8
|
| PubChem CID |
164943
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
477.4ºC at 760 mmHg
|
| Melting Point |
210-212ºC
|
| Flash Point |
242.5ºC
|
| Vapour Pressure |
6.37E-10mmHg at 25°C
|
| LogP |
0.686
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
22
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1CN2CC3=CC4=C(C=C3[C@H]5[C@H]2C1=C[C@@H]([C@H]5O)O)OCO4.Cl
|
| InChi Key |
VUVNTYCHKZBOMV-NVJKKXITSA-N
|
| InChi Code |
InChI=1S/C16H17NO4.ClH/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19;/h3-5,11,14-16,18-19H,1-2,6-7H2;1H/t11-,14-,15+,16+;/m0./s1
|
| Chemical Name |
(1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~77.22 mM)
H2O : ~16.67 mg/mL (~51.49 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4806 mL | 17.4028 mL | 34.8056 mL | |
| 5 mM | 0.6961 mL | 3.4806 mL | 6.9611 mL | |
| 10 mM | 0.3481 mL | 1.7403 mL | 3.4806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
